Literature DB >> 26727417

Malignant hematopoietic cell lines: in vitro models for double-hit B-cell lymphomas.

Hans G Drexler1, Sonja Eberth1, Stefan Nagel1, Roderick A F MacLeod1.   

Abstract

Mature B-cell lymphomas with concurrent rearrangements of MYC and BCL2 (more rarely BCL6), "double-hit lymphomas" (DHLs), form a heterogeneous group. Recent studies have shown that DHLs often present with an aggressive clinical course and a poor prognosis with standard therapy. This distinct clinical entity would benefit from more detailed pathobiological characterization to develop improved treatment options. Lymphoma cell lines are important and informative research tools. Several cell lines have been established from B-cell lymphoma patients harboring MYC rearrangements combined with either (double-hit) or both (triple-hit) BCL2 or BCL6 translocations. All rearrangements have been detected by cytogenetics and validated by FISH. These cell lines provide preclinical models for basic and translational research which speed development of effective treatment strategies.

Entities:  

Keywords:  B-NHL; BCL2; BCL6; FISH; MYC; cell lines; lymphoma

Mesh:

Substances:

Year:  2016        PMID: 26727417     DOI: 10.3109/10428194.2015.1108414

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  11 in total

1.  The BET bromodomain inhibitor CPI203 overcomes resistance to ABT-199 (venetoclax) by downregulation of BFL-1/A1 in in vitro and in vivo models of MYC+/BCL2+ double hit lymphoma.

Authors:  A Esteve-Arenys; J G Valero; A Chamorro-Jorganes; D Gonzalez; V Rodriguez; I Dlouhy; I Salaverria; E Campo; D Colomer; A Martinez; G Rymkiewicz; P Pérez-Galán; A Lopez-Guillermo; G Roué
Journal:  Oncogene       Date:  2018-01-22       Impact factor: 9.867

2.  Therapeutic potential of SGN-CD19B, a PBD-based anti-CD19 drug conjugate, for treatment of B-cell malignancies.

Authors:  Maureen C Ryan; Maria Corinna Palanca-Wessels; Brian Schimpf; Kristine A Gordon; Heather Kostner; Brad Meyer; Changpu Yu; Heather A Van Epps; Dennis Benjamin
Journal:  Blood       Date:  2017-09-13       Impact factor: 22.113

3.  Precision Targeting with EZH2 and HDAC Inhibitors in Epigenetically Dysregulated Lymphomas.

Authors:  Jennifer K Lue; Sathyen A Prabhu; Yuxuan Liu; Yulissa Gonzalez; Akanksha Verma; Prabhjot S Mundi; Nebiyu Abshiru; Jeannie M Camarillo; Swasti Mehta; Emily I Chen; Changhong Qiao; Renu Nandakumar; Serge Cremers; Neil L Kelleher; Olivier Elemento; Jennifer E Amengual
Journal:  Clin Cancer Res       Date:  2019-04-12       Impact factor: 13.801

4.  Diffuse Large B Cell Lymphoma Cell Line U-2946: Model for MCL1 Inhibitor Testing.

Authors:  Hilmar Quentmeier; Hans G Drexler; Vivien Hauer; Roderick A F MacLeod; Claudia Pommerenke; Cord C Uphoff; Margarete Zaborski; Mattias Berglund; Gunilla Enblad; Rose-Marie Amini
Journal:  PLoS One       Date:  2016-12-01       Impact factor: 3.240

5.  Establishment and characterization of a novel 'double-hit' follicular lymphoma cell line, FL-SJC.

Authors:  Min Chen; Guoxiong Jiang; Yichen Liu; Dongya Li; Tiantian Li; Jie Peng; Qian Jiang; Haiyan You; Rong Ba; Jinlan Pan; Mei Li; Weiguo Long; Jinsong Yan; Yan Zhu; Yun Wang; Xiaodong Xi; Jianhua Mao; Xiaofeng Shi
Journal:  J Cell Mol Med       Date:  2020-05-27       Impact factor: 5.310

6.  Generation and characteristics of a novel "double-hit" high grade B-cell lymphoma cell line DH-My6 with MYC/IGH and BCL6/IGH gene arrangements and potential molecular targeted therapies.

Authors:  Hiroaki Kikuchi; Tomonori Higuchi; Yumiko Hashida; Ayuko Taniguchi; Mikio Kamioka; Takahiro Taguchi; Akihito Yokoyama; Ichiro Murakami; Mikiya Fujieda; Masanori Daibata
Journal:  Oncotarget       Date:  2018-09-11

7.  DZNep-mediated apoptosis in B-cell lymphoma is independent of the lymphoma type, EZH2 mutation status and MYC, BCL2 or BCL6 translocations.

Authors:  Chidimma Agatha Akpa; Karsten Kleo; Dido Lenze; Elisabeth Oker; Lora Dimitrova; Michael Hummel
Journal:  PLoS One       Date:  2019-08-16       Impact factor: 3.240

8.  Epstein-Barr virus (EBV) activates NKL homeobox gene HLX in DLBCL.

Authors:  Stefan Nagel; Cord C Uphoff; Wilhelm G Dirks; Claudia Pommerenke; Corinna Meyer; Hans G Drexler
Journal:  PLoS One       Date:  2019-05-29       Impact factor: 3.240

9.  Prohibitin (PHB) expression is associated with aggressiveness in DLBCL and flavagline-mediated inhibition of cytoplasmic PHB functions induces anti-tumor effects.

Authors:  Hafidha Bentayeb; Marine Aitamer; Barbara Petit; Lydie Dubanet; Sabria Elderwish; Laurent Désaubry; Armand de Gramont; Eric Raymond; Agnès Olivrie; Julie Abraham; Marie-Odile Jauberteau; Danielle Troutaud
Journal:  J Exp Clin Cancer Res       Date:  2019-11-04

Review 10.  Deregulated NKL Homeobox Genes in B-Cell Lymphoma.

Authors:  Stefan Nagel; Hans G Drexler
Journal:  Cancers (Basel)       Date:  2019-11-26       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.